Diseases associated with mitochondrial DNA (mtDNA) mutations are highly variable in phenotype, in large part because of differences in the percentage of normal and mutant mtDNAs (heteroplasmy) present within the cell. For example, increasing heteroplasmy levels of the mtDNA tRNA Leu(UUR) nucleotide (nt) 3243A > G mutation result successively in diabetes, neuromuscular degenerative disease, and perinatal lethality. These phenotypes are associated with differences in mitochondrial function and nuclear DNA (nDNA) gene expression, which are recapitulated in cybrid cell lines with different percentages of m.3243G mutant mtDNAs. Using metabolic tracing, histone mass spectrometry, and NADH fluorescence lifetime imaging microscopy in these cells, we now show that increasing levels of this single mtDNA mutation cause profound changes in the nuclear epigenome. At high heteroplasmy, mitochondrially derived acetyl-CoA levels decrease causing decreased histone H4 acetylation, with glutamine-derived acetyl-CoA compensating when glucose-derived acetyl-CoA is limiting. In contrast, α-ketoglutarate levels increase at midlevel heteroplasmy and are inversely correlated with histone H3 methylation. Inhibition of mitochondrial protein synthesis induces acetylation and methylation changes, and restoration of mitochondrial function reverses these effects. mtDNA heteroplasmy also affects mitochondrial NAD + /NADH ratio, which correlates with nuclear histone acetylation, whereas nuclear NAD + /NADH ratio correlates with changes in nDNA and mtDNA transcription. Thus, mutations in the mtDNA cause distinct metabolic and epigenomic changes at different heteroplasmy levels, potentially explaining transcriptional and phenotypic variability of mitochondrial disease. mitochondria | epigenetics | metabolism | transcription | common diseases
Diseases associated with mitochondrial DNA (mtDNA) mutations are highly variable in phenotype, in large part because of differences in the percentage of normal and mutant mtDNAs (heteroplasmy) present within the cell. For example, increasing heteroplasmy levels of the mtDNA tRNA Leu(UUR) nucleotide (nt) 3243A > G mutation result successively in diabetes, neuromuscular degenerative disease, and perinatal lethality. These phenotypes are associated with differences in mitochondrial function and nuclear DNA (nDNA) gene expression, which are recapitulated in cybrid cell lines with different percentages of m.3243G mutant mtDNAs. Using metabolic tracing, histone mass spectrometry, and NADH fluorescence lifetime imaging microscopy in these cells, we now show that increasing levels of this single mtDNA mutation cause profound changes in the nuclear epigenome. At high heteroplasmy, mitochondrially derived acetyl-CoA levels decrease causing decreased histone H4 acetylation, with glutamine-derived acetyl-CoA compensating when glucose-derived acetyl-CoA is limiting. In contrast, α-ketoglutarate levels increase at midlevel heteroplasmy and are inversely correlated with histone H3 methylation. Inhibition of mitochondrial protein synthesis induces acetylation and methylation changes, and restoration of mitochondrial function reverses these effects. mtDNA heteroplasmy also affects mitochondrial NAD + /NADH ratio, which correlates with nuclear histone acetylation, whereas nuclear NAD + /NADH ratio correlates with changes in nDNA and mtDNA transcription. Thus, mutations in the mtDNA cause distinct metabolic and epigenomic changes at different heteroplasmy levels, potentially explaining transcriptional and phenotypic variability of mitochondrial disease. mitochondria | epigenetics | metabolism | transcription | common diseases T he mtDNA is maternally inherited and codes for 13 essential subunits of the mitochondrial energy generating system, oxidative phosphorylation (OXPHOS), plus the 2 rRNAs for the mitochondrial, chloramphenicol (CP)-sensitive, ribosome and the 22 tRNAs required for mitochondrial mRNA translation. Mutations in the mtDNA tRNAs impair the biogenesis of all mtDNA-encoded OXPHOS enzyme complexes, but particularly compromise complex I (NADH:CoQ oxidoreductase), which incorporates 7 of the 13 mtDNA encoded polypeptides (1) .
The overall prevalence of mtDNA mutations is about 1 in 5,000 (2, 3) . This high prevalence of mtDNA diseases results from the high mtDNA mutation rate, which is reflected in 1 in 200 cord bloods harboring 1 of the 10 most common pathogenic mtDNA mutations (4, 5) and 1 in 8 adults harboring a diseaseassociated mutation at ≥1% heteroplasmy (6) .
One of the most common pathogenic mtDNA mutations is the tRNA Leu(UUR) m.3243 A > G mutation, which causes starkly different clinical phenotypes depending on the heteroplasmy levels (1) . At 20% to 30% m.3243G mutant, patients commonly present with type 1 or type 2 diabetes or manifest autism. At 50% to 80% mutant, patients present with myopathy, cardiomyopathy, lactic acidosis, and stroke-like episodes, presenting separately or when in aggregate referred to as the MELAS syndrome. At 90% to 100% mutant, individuals manifest perinatal lethal diseases such as Leigh syndrome.
To investigate the molecular basis of the relationship between the mtDNA heteroplasmy levels and shifts in patient phenotype, we prepared transmitochondrial cybrids with the same nucleus, but with different heteroplasmic percentages of the tRNA Leu(UUR) m.3243G mutation. Cell biological and biochemical characterization of these cybrid cell lines revealed that the physiological parameters of the cybrids mirrored those previously observed in the patients with the same ranges of m.3243G heteroplasmy. Transcriptional analysis by RNA sequencing revealed that cybrids
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with similar heteroplasmy levels corresponding to a set of clinical phenotypes (e.g., 50% to 80% m.3243G associated with neurodegenerative disease) had a similar transcriptional profile, which was strikingly different from transcriptional profiles of cybrids with different heteroplasmy (SI Appendix, Fig. S1 ). Therefore, the marked shifts in the patient phenotypes associated with the different levels of m.3243G heteroplasmy correlate with transcriptional phase shifts in the nuclear gene expression (7) .
The correlation among m.3243G mutant load, transcriptional profile, and clinical phenotype suggests that nDNA transcription responds to signals generated from the mitochondrion. One likely source of such signals are the high-energy mitochondrial intermediates that are the substrates for the posttranslational histone-modifying enzymes. These include ATP for phosphorylation, NAD + for sirtuin-mediated deacetylation, folates for S-adenosylmethionine (SAM) synthesis for methylation, and tricarboxylic acid (TCA) cycle intermediates including acetyl-CoA for histone acetylation and α-ketoglutarate (αKG) for histone demethylation (8) (9) (10) .
To determine whether mtDNA variation affects the nuclear epigenome, we correlated mtDNA tRNA Leu(UUR) m.3243 A > G cybrids' metabolic and redox status with changes in the complete array of nuclear histone modifications. We found multiple associations between metabolites and histone modifications as the level of m.3243 A > G heteroplasmy increased, of which some were observed only at a particular heteroplasmy level. Thus, mtDNA genotype regulates the epigenome through mitochondrial metabolism.
Results
To determine the mitochondrial signals that may regulate the epigenome, we quantified TCA cycle intermediates across our 7 mtDNA tRNA Leu(UUR) nt 3243 A > G patient-derived cybrid lines with heteroplasmy levels of ∼0%, 20%, 30%, 60%, 70%, 90%, and 100% m.3243G mutant, but with the same nuclear DNA. We then correlated the cybrid metabolite levels with all nuclear histone modifications assessed by liquid chromatography mass spectrometry (SI Appendix, Fig. S2 ). The result was an extensive matrix of statistically significant correlations between mitochondrially generated metabolites and histone modifications across the heteroplasmy spectrum (Fig. 1A) , confirming broad spectrum control of nuclear histone modifications by mitochondrial metabolism.
To test whether the differential abundance of the mitochondrial metabolites causes the changes in the histone modifications, we focused on 2 relationships: a positive association between acetylCoA and histone H4 lysines 8 (H4K8) and 16 (H4K16) acetylation (Fig. 1A , blue square #1), and a negative association between the αKG/succinate ratio and histone H3 lysine 9 (H3K9) methylation (Fig. 1A , red square #2). The first association allowed direct examination of acetyl-CoA effect on histone acetylation, as histone H4 tail residues (K5/K8/K12/K16) cannot be methylated. The second association permitted analyzing the effect of αKG level on methylation, as αKG/succinate ratio correlated with H3K9 di-and trimethylation (H3K9me2/3), but not H3K9 acetylation.
Strikingly, these 2 associations show different behaviors across the m.3243G mutant heteroplasmy spectrum. Acetyl-CoA levels and H4K16 acetylation were stable from 0% to 70% mutant mtDNAs, but then declined together at 90% to 100% mutant (R = 0.57; Fig. 1 A, Bottom Right). This decline was confirmed for all H4 residues in independent experiments ( Fig. 1 B and C and SI Appendix, Fig. S3 A-C). In contrast, the αKG/succinate ratio was low at 0% mutant, increased in 30% to 70% mutant, and declined again in 90% to 100% mutant cells. The H3K9 di-and trimethylation showed the inverse pattern, being high at 0% mutant, low at 50% to 70% mutant, and high at 90% to 100% mutant (R = −0.45; Fig. 1 A, Top Right). αKG alone showed a similar pattern (SI Appendix, Fig. S3D ). The inverse αKG-histone methylation association is expected, as Jumonji C (JmjC) histone demethylases known to be active on H3K9 require αKG to demethylate histones and are inhibited by succinate (11) .
Because acetyl-CoA was significantly decreased in 100% mutant cells (Fig. 1A #1 and SI Appendix, Fig. S4 C, Right), but can be generated from multiple sources (12), we sought to determine the contribution of mitochondrial metabolism of glucose in the generation of acetyl-CoA and acetylation of histone H4. We incubated 0% and 100% mutant cells with uniformly 13 C -labeled glucose and traced the label through pyruvate, mitochondrial generation and exportation to the cytosol of citrate, conversion of cytosolic citrate into acetyl-CoA and oxaloacetate by ATPcitrate lyase (13) , and use of the mitochondrially derived acetyl-CoA for histone acetylation (Fig. 2A) . We found that about 70% of acetyl-CoA was derived from 13 C-labeled glucose, and that this was reduced to 45% in the 100% mutant cell line (Fig. 2B) , as in 100% mutant cells, much of the pyruvate was metabolized to lactate, thus limiting acetyl-CoA production (SI Appendix, Fig. S4 A-C) .
To confirm that decreased incorporation of glucose-derived 13 C into acetyl-CoA was a result of the mitochondrial protein synthesis defect, we treated the 0% m.3243G cybrid cells for 7 d with CP to completely block mitochondrial protein synthesis of the 0% mutant cells. CP reduced the transfer of glucose-derived 13 C into acetyl-CoA to ∼2%. Therefore, mitochondria are the major source of acetyl-CoA, and impaired mitochondrial protein synthesis limits mitochondrial acetyl-CoA production. This was confirmed by wash out of CP, resulting in the complete restoration of the incorporation of glucose-derived 13 C into acetyl-CoA (Fig. 2B ). In parallel with the reduced mitochondrial incorporation of glucose-derived 13 C into acetyl-CoA, we assessed the effects of 100% mutant and CP on the acetylation of histone H4 (Fig. 2C) . In the bicolored bar graphs, the total bar height reflects total histone acetylation levels. The different colored subbars represent the time-limited incorporation of the 13 C from the labeled precursor. Both the total steady state histone H4 and 13 Cglucose-derived H4 acetylation were decreased from 50% and 35% in 0% mutant cells to 37% and 15% in 100% mutant cells, respectively (Fig. 2C) . When 0% mutant cells were treated with CP, steady state H4 acetylation was decreased to 40%, but the 13 C-glucose-derived acetylation was eliminated. Following washout of CP, the total steady state H4 acetylation returned to 50% and the glucose-derived 13 C H4 acetylation returned to 35% (Fig. 2C) . Thus, impaired mitochondrial protein synthesis caused by either 100% 3243G mutant mtDNAs or CP inhibition resulted in the depletion of glucose-derived acetyl-CoA and in the reduction of histone H4 acetylation. Mitochondrially derived acetyl-CoA is thus the primary substrate for histone acetylation.
Impairment of mitochondrial protein synthesis resulting from 100% m.3243G mutant mtDNAs or CP inhibition should impair complex I, and thus the mitochondrial oxidation of NADH. The resulting decrease in NAD + should stall the TCA cycle, reducing mitochondrial production of αKG. Because αKG is the required substrate for the JmjC histone demethylases (14) , histone demethylation should be impaired by a protein synthesis defect resulting in increased histone methylation (Fig. 2D) . Both 100% mutant and CP-treated 0% mutant cells showed decreased incorporation of glucose-derived 13 C into αKG, which was restored to normal in CP-treated 0% mutant cells after CP washout (Fig. 2E) . Moreover, although 100% mutant cells did not show an increase in H3K9 trimethylation, likely as a result of decreased SAM production (SI Appendix, Fig. S4D ), the 0% mutant cells treated with CP showed significantly increased levels of H3K9 trimethylation, which returned to normal on CP washout (Fig. 2F) . Thus, inhibition of mitochondrial protein synthesis results in reduced αKG and leads to increased histone methylation, presumably as a result of limiting JmjC-mediated histone demethylation.
To further evaluate the role of NADH oxidation and TCA cycle-mediated acetyl-CoA production, we determined the effect of rotenone, a potent complex I inhibitor, on 13 C-glucosederivation of acetyl-CoA. Rotenone completely eliminated the incorporation of glucose-derived 13 C into acetyl-CoA (Fig. 2G ) and resulted in a significant decrease in the steady state acetylation of H4 histone residues, as well as complete elimination of incorporation of glucose-derived 13 C into H4 acetylation ( Fig.  2H and SI Appendix, Fig. S5 A-F) .
Because acetyl-CoA is essential, depletion of acetyl-CoA by rotenone inhibition of complex I must be compensated. This could occur by the conversion of glutamine to glutamate and then αKG, with αKG being converted to acetyl-CoA by either entering the TCA cycle to generate citrate or by reductive carboxylation (15) . When labeling cells with glutamine-derived 13 C, 0% mutant cells produced about 8% of the acetyl-CoA from glutamine. However, after rotenone inhibition this rose to about 14% (Fig. 2I) . In parallel, glutamine-derived 13 C incorporated 0% cells without and with Rot inhibition; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant; n = 3.
into H4 acetylation increasing from about 14% in 0% mutant cells to about 21% after rotenone inhibition (Fig. 2J and SI Appendix, Fig. S5 G and H) . Thus, glutamine can make a small contribution to acetyl-CoA for histone acetylation.
Rotenone not only depleted glucose-derived 13 C incorporation into αKG (Fig. 2K ) but also resulted in elevated levels of di-and trimethylation and in the di-and trimethylation to monomethylation ratio of H3K9 (Fig. 2L) . Thus, mitochondrially generated αKG must play a role in the activity of the JmjC histone demethylases. NAD + /NADH ratio is crucial in regulating TCA metabolism, and was reduced in 100% mutant cells (SI Appendix, Fig. S4 C, Bottom Left), but it is also known to vary between cellular compartments. To assess subcellular levels of NAD + /NADH ratios, we employed fluorescence lifetime imaging microscopy (FLIM) to quantify NADH lifetimes in the mitochondria and the nucleus of the cybrid cell lines. By FLIM, decreased NADH lifetime correlates with increased free NADH and decreased NAD + /NADH ratio (16) . In the mitochondria, the NAD + /NADH ratio was relatively stable from 0% to 60% heteroplasmy. It began to decline at 70% mutant and then dropped precipitously at 90% and 100% mutant ( Fig. 3 A and B) . Similarly, glucose-derived acetyl-CoA was sustained in 0% to 70% mutant cells, but then dropped precipitously at 90% to 100% m.3243G mutant heteroplasmy (Fig.  3C) . In parallel, glucose-derived H4 acetylation was sustained up to 70% mutant, followed by a drop in the 90% to 100% mutant cells (Fig. 3 D and E) .
When impairment of mitochondrial protein synthesis reaches the level caused by 100% 3243G mutant, respiration is impaired (SI Appendix, Fig. S6B ), the mitochondria can no longer oxidize NADH back to NAD + , the TCA cycle is inhibited, mitochondrial production of glucose-derived acetyl-CoA is reduced, and histone acetylation is limited. This limitation is independent of glucose concentration in the media (SI Appendix, Fig. S7 ).
In the nucleus, the NAD + /NADH ratio declined sharply from that of the 0% mutant cells, reaching a minimum in 20% to 60% mutant cells (Fig. 4 A and B) . The nuclear NAD + /NADH ratio then rose abruptly between 60% and 70% mutant cells to levels well in excess of those of the 0% mutant cells. Finally, the NAD + /NADH ratio declined again at 100% mutant (Fig. 4B) . The sudden rise in NAD + /NADH ratio in the 60% to 70% mutant cells correlated with the induction of genes for de novo NAD + synthesis, starting at 30% mutant, peaking at 70% mutant, and then declining to approximately the 0% level at 100% mutant (Fig. 4C) . The unusual behavior of the nuclear NAD + /NADH ratio exactly corresponds to the striking changes that occurred in the levels of the mtDNA OXPHOS gene mRNAs (Fig. 4 D and E) , suggesting that the nuclear NAD + levels may regulate the activity of the mitochondrial biogenesis genes. Nuclear NAD + levels also correlated with the phase changes in nDNA gene transcription seen between 20% to 30% versus 60% to 90% mutant cells (SI Appendix, Fig.  S1 ). The induction of NAD + synthesis may be a final attempt to reestablish a functional NAD + /NADH redox balance and stimulate mitochondrial OXPHOS.
Discussion
Our work suggests that mtDNA heteroplasmy can result in discrete cellular transcriptional profiles and clinical phenotypes by simultaneously modulating multiple metabolites key to epigenetic signaling (SI Appendix, Fig. S8 ). In contrast to wild-type 0% mutant cells (SI Appendix, Fig. S8 , State A), in the 20% to 30% tRNA Leu(UUR) m.3243 A > G mutant cells, a decline in the nuclear NAD + /NADH ratio is associated with a decline in mtDNA transcripts and a switch from the 0% mutant transcriptional profile to that of the 20% to 30% m.3243 A > G mutant cells (SI Appendix, Figs. S1 and S8, State B). This correlates with the chronic mitochondrial energy deficiency observed in type 2 diabetes (17, 18) and autism (19) . In the 60% to 70% m.3243 A > G mutant cells, the rise in nuclear NAD + levels, corresponding to the induction of NAD + synthesis, is paralleled by an increase in αKG levels and a decline in histone methylation. This correlates with the hyperexpression of the mtDNA genes and the transition to the next discrete cellular transcriptional profile (SI Appendix, Fig. S1 ). This transcription profile corresponds to neuromuscular degenerative disease manifestations and the KEGG-identified transcriptional profiles of Alzheimer, Parkinson, and Huntington diseases ( Figure  5D in ref. 7 and SI Appendix, Fig. S8, State C) . Finally, in the 90% to 100% mtDNA tRNA Leu(UUR) m.3243 A > G mutant cells, the drop in acetyl-CoA levels in association with the decline in histone acetylation is associated with a drop in mtDNA transcripts and the final transition in transcriptional profile (SI Appendix, Figs. S1 and S8, State D), this being associated with perinatal lethal disease (7). Thus, increasing severity of the m.3243G mtDNA genetic defect directly affects mitochondrial metabolites and subcellular redox levels. Our data suggest that these changes cause discrete changes in the epigenomic state that correlate with altered gene transcription and associated clinical manifestations.
Methods
The mtDNA tRNA Leu(UUR) nt 3243A > G Mutation Cybrids. Cell lines harboring different percentages of the mtDNA tRNA Leu(UUR) nt 3243A > G mutation were prepared by fusion of cytoplasts from a heteroplasmic mtDNA tRNA supplemented with 50 μg/mL uridine, nonessential amino acids (1:100, Gibco #11140), and 10% FBS, grown at 37°C in 5% CO 2 (21) .
Cybrid mtDNA tRNA Leu(UUR) nt 3243A > G heteroplasmy levels were quantified by PCR amplification of a 264-nt fragment surrounding the 3243 site and digestion with HaeIII. The cybrid heteroplasmy levels were remarkably stable (SI Appendix, Fig. S9 ).
Cells for analysis of metabolites and histones were grown to ∼80% confluent in DMEM supplemented with 10% FBS, 1 mM glucose, 2 mM glutamine, and 50 ng/L uridine (experimental media). For isotopic experiments, 13 C-uniformly labeled glucose or glutamine and dialyzed serum were employed.
Mitochondrial protein synthesis was inhibited with 100 μg/mL CP for 7 d (22), with inhibition reversed by growth without CP for 3 d. Complex I was inhibited with 1 μM rotenone for 4 h.
Glucose and lactate consumption were analyzed by incubating cells for 4, 8, or 24 h, the medium collected, the glucose and lactate measurement using YSI 2950 Bioanalyzer, and the levels corrected for cell proliferation and media evaporation. Oxygen consumption of digitonin permeabilized cells was analyzed using the Oroboros instrument with 10 6 cells/mL in 2.2 mL of Miro5 buffer (0.5 mM EGTA, 3 mM MgCl 2 0.6 H 2 O, 60 mM K-lactobionate, 20 mM Taurine, 10 mM KH 2 PO 4 , 20 mM Hepes, 110 mM Sucrose, 1 g/L fatty acid free BSA at pH 7.0 with KOH). Substrates and complex inhibitors were added as in SI Appendix, Fig. S6 .
Acetyl-CoA/Free CoA, SAM, and Organic Acid Measurement. Cells were cultured for 12 h in DMEM with 4.5 g/L glucose, 10% FBS, 50 μg/mL uridine, 1 mM sodium pyruvate, 1× NEAA and 2 mM glutamine; harvested; and frozen for 10 s in liquid nitrogen and stored in −80°C. The concentration of amino acids was determined by Agilent 1260 HPLC system, using precolumn derivatization with o-phthalaldehyde (23). Short-chain Acyl-CoAs and SAM levels were determined by Agilent LC/MS 6410 Triple Quad system using 872-365 multiple reaction monitoring (MRM) for Benzoyl-CoA (Internal standard), 868-361 MRM for Succinyl-CoA, 854-347 MRM for Malonyl-CoA, 838-331 MRM for Butyryl-CoA, 824-317 MRM for Propionyl-CoA, 810-303 MRM for Acetyl-CoA, 768-261 for free CoA, and 399-250 MRM for SAM. Organic acids levels were determined by the isotope-dilution approach and GC-MS system (24) .
Acyl-CoA and Polar Metabolite Quantification and Isotopologue Analysis. After 16 h growth in normal media, cells were incubated in experimental media containing labeled metabolites for 4 h. For acyl-CoA quantification, the attached cells were fixed by the addition of 1 mL ice-cold 10% (wt/vol) trichloroacetic acid, harvested by scrapping, disrupted by pulse-sonication (sonic dismembrator, Fisher Scientific), and the protein sedimented at 17,000 rcf for 10 min at 4°C. Supernatants were purified using Oasis HLB 1-mL (30 mg) solid-phase extraction columns (Waters), conditioned with methanol and water. The supernatants were applied to the columns, the columns washed with 1 mL H 2 O, the analytes eluted with methanol containing 25 mM ammonium acetate, dried with N 2 gas, and resuspended in 50 μl of 5% 5-sulfosalicylic acid. For quantification, 0.1 mL of internal standard was added containing [ drying with N 2 gas, and resuspension in 5-sulfosalicylic acid. Samples were analyzed using an Ultimate 3000 Quaternary UHPLC coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) operating in the positive ion mode (26, 27) . For 13 C tracing experiments, isotopic enrichment was calculated using the FluxFix online calculator (28) .
Histone Extraction and Western Blot Analysis. For histone extraction, cells were switched to experimental media, washed with ice-cold PBS, and 0.5 mL of nuclei isolation buffer (NIB-250) added and incubated for 5 min. NIB-250 is 15 mM Tris· HCl at pH 7.5, 60 mM KCl, 15 mM NaCl, 5 mM MgCl 2 , 1 mM CaCl 2 , and 250 mM sucrose, to which was added 1 mM DTT, 10 mM sodium butyrate, 1× Protein Inhibitor Mixture (Sigma), and 0.1% Nonidet P-40 (Sigma). Cells were harvested by scrapping, pelleted at 600 rcf for 5 min at 4°C, washed twice with NIB-250 without Nonidet P-40, and pelleted. Histones were extracted in 0.8 mL 0.4 N H 2 SO 4 for 2 h at 4°C, the insoluble fraction pelleted at 11,000 rcf for 10 min in 4°C, and the soluble fraction containing histones precipitated with 0.2 mL 100% TCA at 4°C overnight. The film-like pellet of histone was sedimented at 11,000 rcf for 10 min at 4°C, washed with ice-cold 1 mL acetone with 0.1% HCl plus 2 washes in ice-cold pure acetone, air-dried, and stored at −80°C for Western blotting or mass spectrometry analysis.
For Western blotting, 0.5 to 1 μg of histone extract was electrophoresed on a gradient 4% to 12% Bis-Tris gel at 120 V for 60 min, and the proteins transferred onto a 0.2 cellulose membrane in methanol buffer overnight. Membranes were blocked in 5% dry milk, incubated in primary antibody (H4K5ac, Millipore 07-327; H4, ab10158; H3, ab1791) for 2 h, washed 3 times incubated with secondary horseradish-peroxidase conjugated antibody for 1 h, and peroxidase stained (Biorad Gel-Doc XR).
Histone Modification Quantification and Isotopologue Analysis. Histones were extracted from cells incubated in experimental media containing labeled metabolites for 4 h. For mass spectrometer analysis, histones were derivatized using propionic anhydride, digested using trypsin, and the new N-termini were also derivatized. The resulting samples were stage-tipped and subjected to mass spectrometer analysis, using 0.1% formic acid in water and 0.1% formic acid in acetonitrile as buffers, with separation carried out on a C18 column (29) . Data acquisition used high-resolution DIA and the data processed using EpiProfile software (30) .
NADH FLIM. FLIM microscopy of NADH (NADH FLIM) (16) was performed on cells grown in glass-bottom dishes (Greiner, 627870) with the medium changed to Tyrodes buffer (pH 7.4) and the cells incubated for 4 h at 37°C in room air. The cultures were then placed in the microscope chamber 15 min before image acquisition, with FLIM imaged used a Zeiss LSM 710 laser scanning microscope equipped with a femtosecond pulsed 2-photon laser (80 MHz, Coherent). NADH was excited at 730 nm with a laser power of <5 mW and fluorescence monitored using time-correlated single photon counting (HPM-100-40, Becker and Hickl) through a 680-nm short-pass and 460/50 bandpass filter. Data were recorded using SPCM 9.77 and subsequently analyzed using SPCImage 6.2 assuming a biexponential decay with fixed τ1 = 400 ps and τ2 = 2,500 ps for free and protein-bound NADH. Proper fitting of the lifetime curve was evaluated using χ2, and the mean lifetime (τmean) was calculated.
Total Cellular NAD + /NADH Ratio Measurement. NAD + /NADH levels were analyzed for cells grown for 12 h in DMEM with 4.5 g/L glucose, 10% FBS, 50 μg/mL uridine, 1 mM sodium pyruvate, 1× NEAA and 2 mM glutamine, then collected and frozen for 10 s in liquid nitrogen and stored in −80°C. Frozen pellets were resuspended in Tris buffer (pH = 8) and half extracted with perchloric acid and half with alkaline buffer. After filtration, samples were loaded onto a HPLC system, using an YMC-Pack ODS-A column (5 μm, 4.6 × 250 mm) preceded by a guard column. NAD + and NADH peak areas were integrated by the Shimadzu Lab Solution software with standard curves normalized to protein (31) .
RNA-Sequencing Data Analysis. RNA-sequence data were used to determine expression levels of the NAD + biosynthetic genes (7), reported as reads per kilobase per million reads normalized to 0% m.3243G.
Data Analysis and Statistical Methods. R software (3.4.2) was used for metabolite-histone correlations; Spearman correlation for correlating dependent variables across heteroplasmy spectrum; and unpaired, 2-tailed, t test (Prism software) for individual comparisons. For hierarchical clustering, P values were adjusted using the FDR method with false-positive discovery rate of 1%.
